Degarelix
Clinical data | ||
---|---|---|
Trade names | Firmagon, others | |
Other names | FE-200486 | |
AHFS/Drugs.com | Monograph | |
MedlinePlus | a609022 | |
License data | ||
Pregnancy category | ||
GnRH antagonist; Antigonadotropin | ||
ATC code | ||
Legal status | ||
Legal status | ||
JSmol) | ||
| ||
| ||
(what is this?) (verify) |
Degarelix, sold under the brand name Firmagon among others, is a
Medical uses
The GnRH antagonist degarelix, through its ability to reduce serum testosterone, is used to treat hormone-sensitive prostate cancer.[7]
Side effects
Degarelix is commonly associated with hormonal side effects such as
Pharmacology
GnRH antagonists (
Unlike GnRH agonists, which cause an initial stimulation of the
GnRH antagonists have an immediate onset of action leading to a fast and profound suppression of testosterone and are therefore especially valuable in the treatment of patients with prostate cancer where fast control of disease is needed.[medical citation needed]
History
In December 2008, the US Food and Drug Administration (FDA) approved degarelix for the treatment of people with advanced prostate cancer.[13][14] It was subsequently approved by the European Commission at the recommendation of the European Medicines Agency (EMA) in February 2009, for use in adult males with advanced, hormone-dependent prostate cancer.[4] Ferring Pharmaceuticals markets the drug under the name Firmagon.[4]
Research
Degarelix is studied for use as a chemical castration agent on men with pedophilia in Sweden.[15] A study demonstrated a reduced the risk score for committing child sexual abuse in men with pedophilic disorder two weeks after initial injection.[16]
See also
References
- ^ a b "Degarelix (Firmagon) Use During Pregnancy". Drugs.com. 3 February 2020. Archived from the original on 26 February 2020. Retrieved 25 February 2020.
- ^ "Firmagon 120mg Injection - Summary of Product Characteristics (SmPC)". (emc). 15 January 2020. Archived from the original on 26 February 2020. Retrieved 25 February 2020.
- ^ a b "Firmagon- degarelix kit". DailyMed. 18 September 2019. Archived from the original on 12 August 2020. Retrieved 26 February 2020.
- ^ a b c "Firmagon EPAR". European Medicines Agency (EMA). 10 January 2020. Archived from the original on 26 February 2020. Retrieved 25 February 2020.
- ^ "Degarelix Acetate Monograph for Professionals". Drugs.com. 7 October 2019. Archived from the original on 26 February 2020. Retrieved 25 February 2020.
- S2CID 2892725.
- ^ PMID 28480768.
- PMID 18801505.
- PMID 18538469.
- ^ "Firmagon "Ferring Pharmaceuticals A/S" - Felleskatalogen". www.felleskatalogen.no. Archived from the original on 28 November 2020. Retrieved 5 May 2020.
- S2CID 8280692.
- PMID 18407326.
- ^ "Drug Approval Package: Degarelix NDA #022201". U.S. Food and Drug Administration (FDA). Archived from the original on 9 August 2020. Retrieved 29 September 2020.
- ^ "FDA Approves Ferring Pharmaceuticals' Degarelix (Generic Name) for Treatment of Advanced Prostate Cancer" (Press release). Ferring Pharmaceuticals. 24 December 2008. Archived from the original on 8 June 2011. Retrieved 25 February 2020 – via PR Newswire.
- ^ "Pedofiler ska stoppas – med kemisk kastrering". Expressen. Archived from the original on 26 February 2021. Retrieved 4 August 2016.
- PMID 32347899.